Dr. Wenche Rolfsen
Dr. Wenche Rolfsen
Chairman of the board since 2011
Read more
Dr. Wenche Rolfsen
Dr. Wenche Rolfsen
Chairman of the board since 2011

Born: 1952.

Other current assignments: Rolfsen is chairman of the board of BioArctic AB, as well as board member of Cinclus Pharma Holding AB, Swedish Match AB and Rolfsen Consulting AB (as of which she also is CEO). Rolfsen is partner in Serendipity Partners.

Experience: Rolfsen has 16 years’ experience in leading positions within pre-clinical research and development at Pharmacia AB. She has been responsible for the early clinical organization at Quintiles Europe and CEO of Quintiles Scandinavia for a total of 11 years. Moreover, she has been a board member of several listed companies since 2005. She holds a PhD in Pharmacology from Uppsala University where she also was associate professor during 9 years.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Direct holding of 113 400 shares and indirect holding of 487 344 shares.

Marlene Forsell
Marlene Forsell
Board member since april 2020
Read more
Marlene Forsell
Marlene Forsell
Board member since april 2020

Born: 1976

Other current assignments: Forsell is board member of Nobia AB, STG Group AS, Kambi Group Plc och Lime Technologies AB.

Experience: Forsell was CFO for Swedish Match AB in 2013-2018 and previously held several leading financial positions in the same company. Before Forsell was employed by Swedish Match AB in 2004, she worked at Ernst & Young with transaction consulting. Forsell holds a Master of Business Administration degree from the Stockholm School of Economics.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: –

Prof. Uli Hacksell
Prof. Uli Hacksell
Board member since 2015
Read more
Prof. Uli Hacksell
Prof. Uli Hacksell
Board member since 2015

Born: 1950.

Other current assignments: Hacksell is board member of Medivir AB, Active Biotech AB, SynAct Pharma AB and Beactica Therapeutics AB.

Experience: Hacksell has over 25 years of international R&D management experience from both large pharmaceutical and biotech companies as well as over 10 years of experience as public company CEO. Hacksell has been CEO and chairman of the board of Cerecor.Hacksell was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from being a private start-up to becoming a public multibillion dollar company. He has previously held various senior executive positions at Astra AB and has held the position of professor in organic chemistry at Uppsala University. He has a PhD from Uppsala University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Direct holding of 408 000 shares.

Dr. Lennart Hansson
Dr. Lennart Hansson
Board member since 2011
Read more
Dr. Lennart Hansson
Dr. Lennart Hansson
Board member since 2011

Born: 1956.

Other current assignments: Hansson is chairman of the board of Ignitus AB, Cinclus Pharma Holding AB and Sixera Pharma AB as well as board member of Medivir AB and Calliditas Therapeutics AB.

Experience: Former head of Life Science Investments at Industrifonden. Previously Hansson has more than 25 years’ experience from pharma and biotech industry in executive position at KabiGen, Symbicom AB, AstraZeneca AB, Karolinska Development AB and BioVitrum AB and as CEO for Arexis AB. He has a PhD from Umeå University.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Indirect holding of 432 000 shares.

Dr Yilmaz Mahshid
Dr Yilmaz Mahshid
Board member since April 2020
Read more
Dr Yilmaz Mahshid
Dr Yilmaz Mahshid
Board member since April 2020

Born: 1979

Other current assignments: Mahshid is CEO of Medivir AB and board member of Mahshid Advisors AB and Venaticus Capital AB.

Experience: Mahshid was previously CFO of PledPharma AB. Mahshid was previously employed by Industrifonden where, as Investment Manager & Controller, he was part of the life science team. He has previous experience from positions as health care analyst at Pareto Securities and Öhman Fondkommission. He started his career as a researcher at the Karolinska Institutet and then at the pharmaceutical companies Biolipox and Orexo. Mahshid has a PhD from the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: –

Stig Lökke Pedersen
Stig Lökke Pedersen
Board member since 2012
Read more
Stig Lökke Pedersen
Stig Lökke Pedersen
Board member since 2012

Born: 1961.

Other current assignments: Pedersen is chairman of the board of Moksha8 Ltd, Union Therapeutics A/S, Stemform A/S and SSI-Diagnostics A/S as well as board member of Hasle Refractories A/S, TAP A/S, SkyBrands A/S and BroenLab A/S. Furthermore Stig Lökke Pedersen is operating partner of Catacap A/S.

Experience: Pedersen was during a period of nearly 20 years part of the management team of the Danish pharmaceutical group H. Lundbeck A/S, including 10 years as executive VP and member of Lundbeck’s group management. From 2005 to 2011, Pedersen was also Chief Commercial Officer and responsible for Lundbeck’s global sales and marketing activities. The years prior to Lundbeck he worked for Ciba-Geigy AG (now Novartis) during a number of years in Denmark, Switzerland and South Africa. Pedersen has altogehter worked for more than 30 years in the pharmaceutical industry and also has extensive experience from listed companies.He holds a Master’s degree in economics from the University of Aalborg.

Independent of InDex and the senior management: Yes.

Independent of major shareholders: Yes.

Shareholding in InDex: Indirect holding of 382 152 shares.